- Home
- ESPR vs SPOK Comparison
ESPR vs SPOK Comparison
Compare ESPR & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- SPOK
- Stock Information
- Founded
- ESPR 2008
- SPOK 2004
- Country
- ESPR United States
- SPOK United States
- Employees
- ESPR N/A
- SPOK N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- ESPR Health Care
- SPOK Telecommunications
- Exchange
- ESPR Nasdaq
- SPOK Nasdaq
- Market Cap
- ESPR 305.0M
- SPOK 329.2M
- IPO Year
- ESPR 2013
- SPOK 1992
- Fundamental
- Price
- ESPR $1.61
- SPOK $15.91
- Analyst Decision
- ESPR Buy
- SPOK Hold
- Analyst Count
- ESPR 7
- SPOK 1
- Target Price
- ESPR $6.36
- SPOK $15.00
- AVG Volume (30 Days)
- ESPR 4.2M
- SPOK 155.3K
- Earning Date
- ESPR 03-04-2025
- SPOK 04-30-2025
- Dividend Yield
- ESPR N/A
- SPOK 7.85%
- EPS Growth
- ESPR N/A
- SPOK N/A
- EPS
- ESPR N/A
- SPOK 0.73
- Revenue
- ESPR $332,314,000.00
- SPOK $137,653,000.00
- Revenue This Year
- ESPR $5.51
- SPOK $3.51
- Revenue Next Year
- ESPR $1.42
- SPOK N/A
- P/E Ratio
- ESPR N/A
- SPOK $21.82
- Revenue Growth
- ESPR 185.66
- SPOK N/A
- 52 Week Low
- ESPR $1.47
- SPOK $13.24
- 52 Week High
- ESPR $3.94
- SPOK $17.96
- Technical
- Relative Strength Index (RSI)
- ESPR 48.04
- SPOK 41.01
- Support Level
- ESPR $1.47
- SPOK $15.70
- Resistance Level
- ESPR $1.61
- SPOK $16.86
- Average True Range (ATR)
- ESPR 0.13
- SPOK 0.39
- MACD
- ESPR 0.01
- SPOK -0.08
- Stochastic Oscillator
- ESPR 51.28
- SPOK 26.53
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.